Galapagos increases share capital through warrant exercises
September 21 2017 - 4:01PM
Mechelen, Belgium; 21 September 2017, 22.00
CET; regulated information - Galapagos NV (Euronext & NASDAQ:
GLPG) announces a share capital increase arising from warrant
exercises.
Galapagos issued 28,100 new ordinary shares on
21 September 2017, for a total capital increase
(including issuance premium) of €268,478.00.
Pursuant to the warrant exercise program of
Galapagos' executive committee, executive committee members
automatically are committed to exercise a minimum number of
warrants, subject to certain conditions. In accordance with the
rules of this program, CEO Onno van de Stolpe exercised 15,000
warrants and two other executive committee members exercised an
aggregate number of 10,000 warrants.
In accordance with Belgian transparency
legislation[1], Galapagos notes that its total share capital
currently amounts to €275,287,943.48, the total number of
securities conferring voting rights is 50,895,778, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
4,011,807, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have
any convertible bonds or shares without voting rights
outstanding.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical
and discovery studies in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring
this JAK1-selective inhibitor for inflammatory indications to
patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including
fee-for-service subsidiary Fidelta, has approximately 550
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors:Elizabeth GoodwinVP IR & Corporate
Communications +1 781 460 1784
Paul van der HorstDirector IR & Business Development +31 71
750 6707ir@glpg.com
Media:Evelyn FoxDirector Communications +31 6 53 591 999
communications@glpg.com
Forward-looking statementsThis release may contain
forward-looking statements. Such forward-looking statements are not
guarantees of future results. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
forward-looking statements in this document, unless specifically
required by law or regulation.
[1] Belgian Act of 2 May 2007 on the
disclosure of major shareholdings in issuers whose shares are
admitted to trading on a regulated market
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1938577c-0a3d-461c-b5e9-4b7c7a4c43a3
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024